CIK 0001531177 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Sight Sciences, Inc.
Sign in to watch- Ticker
- SGHT
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 800625749
- Phone
- (415) 889-0550
- Business address
- 4040 CAMPBELL AVE,, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $652,777
- in 5 filings, $653K under 10b5-1 plans
Net −$652,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Badawi Paul −$268K President and CEO sold <1% of stake
- Bauerlein Alison −$224K Chief Operating Officer sold 4% of stake
- Badawi David −$71K Chief Technology Officer sold <1% of stake
- Rodberg James −$64K Chief Financial Officer sold 3% of stake
- Taylor Brenton −$26K EVP, Operations & R&D sold 1% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-06 | Encrantz Staffan Director | Purchase | +27,900 | $4.22 | $118K | 1,377,964 |
| 2025-06-05 | Mazzacco Catherine Director | Grant or award | +30,952 | 78,507 | ||
| 2025-06-05 | Larsen-Becker Brenda Jane Director | Grant or award | +30,952 | 79,040 | ||
| 2025-06-05 | Rogers Erica J. Director | Grant or award | +30,952 | 175,352 | ||
| 2025-06-05 | Fountain Tamara Director | Grant or award | +30,952 | 81,389 | ||
| 2025-06-05 | Zurbay Donald Director | Grant or award | +30,952 | 165,352 | ||
| 2025-06-05 | Encrantz Staffan Director | Purchase | +40,951 | $4.24 | $174K | 1,319,112 |
| 2025-06-05 | Encrantz Staffan Director | Grant or award | +30,952 | 1,350,064 | ||
| 2025-06-04 | Encrantz Staffan Director | Purchase | +21,674 | $4.17 | $90K | 1,278,161 |
| 2025-06-03 | Encrantz Staffan Director | Purchase | +25,230 | $3.97 | $100K | 1,256,487 |
| 2025-06-02 | Encrantz Staffan Director | Purchase | +30,799 | $3.88 | $119K | 1,231,257 |
| 2025-05-30 | Encrantz Staffan Director | Purchase | +42,753 | $3.67 | $157K | 1,200,458 |
| 2025-05-29 | Encrantz Staffan Director | Purchase | +60,128 | $3.59 | $216K | 1,157,705 |
| 2025-05-28 | Encrantz Staffan Director | Purchase | +26,715 | $3.52 | $94K | 1,097,577 |
| 2025-05-27 | Encrantz Staffan Director | Purchase | +41,346 | $3.44 | $142K | 1,070,862 |
| 2025-05-19 | Bauerlein Alison Chief Financial Officer | Sale | −13,066 | $3.48 | $45K | 636,728 |
| 2025-05-16 | Raheja Manohar K. EVP, Research & Development | Grant or award | +12,767 | $3.02 | $39K | 167,767 |
| 2025-05-16 | Link Matthew Chief Commercial Officer | Grant or award | +6,631 | $3.02 | $20K | 837,182 |
| 2025-05-12 | Burbach Gerhard F Director | Grant or award | +74,766 | 94,766 | ||
| 2025-04-02 | HAYDEN JEREMY B. Chief Legal Officer | Sale | −9,395 | $2.31 | $22K | 275,481 |
Page 5 of 7 · 126 trades